Overview

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination With Temozolomide in Patients With Recurrent or Progressive Glioblastoma Multiforme (GBM)

Status:
Recruiting

Trial end date:
2024-10-31

Target enrollment:

Participant gender:

Summary

This is a Phase 1 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)

Phase:

Phase 1

Details

Lead Sponsor:

BeyondBio Inc.

Treatments:

Temozolomide